Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cumberland Pharmaceuticals

4.97
+0.480010.69%
Post-market: 4.970.00000.00%17:43 EDT
Volume:43.57K
Turnover:213.01K
Market Cap:69.42M
PE:-10.78
High:5.15
Open:4.56
Low:4.56
Close:4.49
Loading ...

FDA APPROVES ACETADOTE® sNDA

PR Newswire
·
10 Dec 2024

Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)

Simply Wall St.
·
10 Nov 2024

Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...

GuruFocus.com
·
09 Nov 2024

Cumberland Q3 Adj $(0.02) Down From $0.02 YoY, Sales $9.09M Down From $10.09M YoY

Benzinga
·
08 Nov 2024

Cumberland: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

Cumberland Pharmaceuticals Q3 Adjusted EPS USD -0.02

THOMSON REUTERS
·
08 Nov 2024

Cumberland receives FDA orphan, RPDD designation for Ifetroban

TIPRANKS
·
07 Nov 2024

BRIEF-Cumberland Pharmaceuticals Receives FDA Orphan Drug And Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy

Reuters
·
07 Nov 2024

Cumberland Pharmaceuticals Receives FDA Orphan Drug and Rare Pediatric Disease Designations for New Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
07 Nov 2024

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

PR Newswire
·
07 Nov 2024

Cumberland announces publication comparing Caldolor and ketorolac

TIPRANKS
·
06 Nov 2024

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

PR Newswire
·
06 Nov 2024

Rpt-Cumberland Pharmaceuticals : Does Not Believe CMS's Determination Regarding Caldolor Is Consistent With Intent of Nopain Legislation

THOMSON REUTERS
·
05 Nov 2024

Rpt-Cumberland Pharmaceuticals Inc: CMS Excludes Caldolor From Nopain Act Separate Payment List

THOMSON REUTERS
·
05 Nov 2024

Corrected-Cumberland Pharmaceuticals Inc: Evaluating Options for Caldolor Payment (Removes Extraneous Word 'CMS')

THOMSON REUTERS
·
05 Nov 2024

Cumberland Pharmaceuticals : Does Not Believe CMS's Determination Regarding Caldolor Is Consistent With Intent of Nopain Legislation

THOMSON REUTERS
·
05 Nov 2024

Cumberland Pharmaceuticals Inc: CMS Evaluating Options for Caldolor Payment

THOMSON REUTERS
·
05 Nov 2024

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

PR Newswire
·
01 Nov 2024